United States Biotechnology & Medical Research

Foghorn Therapeutics Inc. (FHTX)

Track

Track

Foghorn Therapeutics Inc. experienced multiple planned and proposed sales by executives during September 2024. Chief People Officer Carlos Costa and Chief Scientific Officer Steven Bellon executed these divestments. No insider trading activity has occurred within the last three months, rendering recent market performance metrics irrelevant to these historical equity movements.
Ticker: FHTX Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Foghorn Therapeutics Inc.. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Costa Carlos Chief People Officer Officer
Transaction date
Planned sale
Price
418.58
Quantity 62,580 +37.0%
Value US$3,468,063
Costa Carlos Chief People Officer Officer
Transaction date
Planned sale
Price
252.39
Quantity 55,524 +3.7%
Value US$2,431,210
Costa Carlos Chief People Officer Officer
Transaction date
Planned sale
Price
489.78
Quantity 53,847 -15.9%
Value US$804,698
Costa Carlos Chief People Officer Officer
Transaction date
Planned sale
Price
10.04
Quantity 10,272 -100.0%
Value US$103,131
Costa Carlos Chief People Officer Officer
Transaction date
Planned sale
Price
10.00
Quantity 400 -100.0%
Value US$4,000
CARLOS COSTA Officer Officer
Transaction date
Proposed sale
Price
9.72
Quantity 98,648
Value US$958,859
Bellon Steven F. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
9.50
Quantity 20,000 -16.4%
Value US$190,000
STEVEN BELLON Officer Officer
Transaction date
Proposed sale
Price
7.53
Quantity 20,000
Value US$150,600
2.3
Cavalie Fanny Chief Strategy/Bus Ops Officer Officer
Transaction date
Sale
Price
6.56
Quantity 11,000 -12.6%
Value US$72,134
Agresta Samuel Chief Medical Officer Officer
Transaction date
Sale
Price
8.25
Quantity 311,297 -100.0%
Value US$2,568,200
SAMUEL AGRESTA Officer Officer
Transaction date
Proposed sale
Price
8.25
Quantity 311,297
Value US$2,568,200
3.0
DECICCO CARL Chief Scientific Officer Officer
Transaction date
Purchase
Price
16.00
Quantity 5,500 +2.2%
Value US$88,000
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2024-09-24 2024-09-23 PlS Planned sale
Costa Carlos

Chief People Officer

Officer
62,580 +37.0%
418.58
US$3,468,063 		62,580 +37.0% 418.58 US$3,468,063
2024-09-24 2024-09-20 PlS Planned sale
Costa Carlos

Chief People Officer

Officer
55,524 +3.7%
252.39
US$2,431,210 		55,524 +3.7% 252.39 US$2,431,210
2024-09-20 2024-09-18 PlS Planned sale
Costa Carlos

Chief People Officer

Officer
53,847 -15.9%
489.78
US$804,698 		53,847 -15.9% 489.78 US$804,698
2024-09-18 2024-09-17 PlS Planned sale
Costa Carlos

Chief People Officer

Officer
10,272 -100.0%
10.04
US$103,131 		10,272 -100.0% 10.04 US$103,131
2024-09-18 2024-09-16 PlS Planned sale
Costa Carlos

Chief People Officer

Officer
400 -100.0%
10.00
US$4,000 		400 -100.0% 10.00 US$4,000
2024-09-16 2024-09-16 PrS Proposed sale
CARLOS COSTA

Officer

Officer
98,648
9.72
US$958,859 		98,648 9.72 US$958,859
2024-09-11 2024-09-09 PlS Planned sale
Bellon Steven F.

Chief Scientific Officer

Officer
20,000 -16.4%
9.50
US$190,000 		20,000 -16.4% 9.50 US$190,000
2024-09-09 2024-09-09 PrS Proposed sale
STEVEN BELLON

Officer

Officer
20,000
7.53
US$150,600 		20,000 7.53 US$150,600
2024-03-12 2024-03-11 S Sale
2.3
Cavalie Fanny

Chief Strategy/Bus Ops Officer

Officer
11,000 -12.6%
6.56
US$72,134 		11,000 -12.6% 6.56 US$72,134
2023-08-18 2023-08-16 S Sale
Agresta Samuel

Chief Medical Officer

Officer
311,297 -100.0%
8.25
US$2,568,200 		311,297 -100.0% 8.25 US$2,568,200
2023-08-16 2023-08-16 PrS Proposed sale
SAMUEL AGRESTA

Officer

Officer
311,297
8.25
US$2,568,200 		311,297 8.25 US$2,568,200
2020-10-29 2020-10-27 B Purchase
3.9
Flagship Ventures Fund V General Partner LLC
Large shareholder
50,000 +2.8%
16.00
US$800,000 		50,000 +2.8% 16.00 US$800,000
2020-10-29 2020-10-27 B Purchase
3.9
Flagship Ventures Fund V General Partner LLC
Large shareholder
50,000 +3.5%
16.00
US$800,000 		50,000 +3.5% 16.00 US$800,000
2020-10-29 2020-10-27 B Purchase
3.9
Flagship Ventures Fund V General Partner LLC
Large shareholder
50,000 +0.5%
16.00
US$800,000 		50,000 +0.5% 16.00 US$800,000
2020-10-29 2020-10-27 B Purchase
3.0
DECICCO CARL

Chief Scientific Officer

Officer
5,500 +2.2%
16.00
US$88,000 		5,500 +2.2% 16.00 US$88,000
2020-10-28 2020-10-27 B Purchase
3.0
Abu Dhabi Investment Authority

Former 10% Owner
150,000 +13.9%
16.00
US$2,400,000 		150,000 +13.9% 16.00 US$2,400,000
Explore more

More insider trading research around Foghorn Therapeutics Inc.

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America